DELRAY BEACH, Fla., Aug. 2, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (Nasdaq:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that it has been awarded an additional important international patent "Apparatus and Method of Extracting and Optically Analyzing an Analyte from a Fluid-based Sample," (WO2008/005166) by the World Intellectual Property Organization. The technology represented by this new patent, awarded to the Company's MicroFluidic Systems ("MFS") subsidiary, works in conjunction with the patented technology which the Company announced in mid-July. The technologies provide key steps in accurate biological sample preparation and detection with limited resources, and in the field or clinical environment.
The handheld instrument is small enough, about the size of a syringe, that it could be carried easily by a medical provider and used with a minimal amount of training and time. This technology can allow rapid detection within minutes of a sampling allowing appropriate treatment for infected individuals immediately. The system works entirely on batteries.
Dr. M. Allen Northrup, CEO of MFS, said, "The two new patents announced over the past couple of weeks are noteworthy for their ability to run biological sample analysis in a small, portable and cost-efficient format and provide rapid, accurate detection. We believe this technology has significant value for multiple applications of critical importance to prevent disease outbreaks and save lives."
The unique component of the technology is a very low power optical analysis system directly coupled to the collection system to perform optical analysis on multiple collected analytes. The purification device includes a plurality of capture surfaces coated with specific capture chemistries. The specific capture can be for a nucleic acid, protein or other target analyte, and multiple options for optical detection exist.
PositiveID acquired MFS in May 2011. MFS specializes in the production of automated instruments for a wide range of applications in the detection and processing of biological samples. MFS' strong portfolio of intellectual property related to sample preparation and rapid medical testing applications are complementary to PositiveID's portfolio of virus detection and diabetes management products.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and biological detection systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com. ;
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the likelihood that this portable technology can be used to detect pathogens in both field and clinical environments for rapid diagnosis and treatment; the likelihood that the technologies provide key steps in accurate biological sample preparation and detection with limited resources, and in the field or clinical environment; the ability of this technology to allow rapid detection within minutes of a sampling allowing appropriate treatment to infected individuals immediately; the likelihood that this technology has significant value for multiple applications of critical importance to prevent disease outbreaks and save lives; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to integrate this technology into new diagnostic products for rapid biological detection, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Q filed on May 13, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.